LIGAND PHARMACEUTICALS INCORPORATED

LGNXZ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $38.9M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $39.9M
SG&A Expense $15.2M
Operating Income $-10.0M
Operating Margin -25.6%
Interest Expense $270.0K
Pretax Income $-9.9M
Income Tax Expense $-1.5M
Net Income $-1.9M
Net Margin -5.0%
EPS (Basic) $-0.10
EPS (Diluted) $-0.10
Shares Outstanding (Basic) 18.9M
Shares Outstanding (Diluted) 18.9M
Dividends Per Share
← Newer Page 3 of 3 Older →